Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06789445 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
A Phase 1 study of Retinal Degeneration and Cone-Rod Dystrophy, sponsored by BlueRock Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT06789445: Recruiting Phase 1 study of Retinal Degeneration and Cone-Rod Dystrophy, sponsored by BlueRock Therapeutics.
NCT06789445 is a Phase 1 study of Retinal Degeneration and Cone-Rod Dystrophy that is actively recruiting participants, run by BlueRock Therapeutics. The registered enrollment target is 54 participants, below the 338-participant average among 17 other Retinal Degeneration trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06789445, a Phase 1 study of Retinal Degeneration and Cone-Rod Dystrophy, is actively recruiting participants, sponsored by BlueRock Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.
Conditions Studied
Interventions
- BIOLOGICAL OpCT-001
Study Locations (3)
Florida
- University of Miami, Bascom Palmer Eye Institute - Miami
Texas
- Retina Foundation of the Southwest - Dallas
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2030-10 |
| Phase | Phase 1 |
What NCT06789445 shows while recruiting
NCT06789445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 338-participant average among 17 other Retinal Degeneration trials with a reported enrollment target (84% lower).
The record links to 9 conditions, with Retinal Degeneration appearing as the primary indexed condition, and to 1 intervention - of which OpCT-001 is the first listed.
NCT06789445 reports a single indexed study location in Florida, Texas, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06789445 about?
NCT06789445 is a clinical study titled "A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)". Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 will focus on safety and features a dose-e...
What is the current status of trial NCT06789445?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2025-03-10. Estimated completion is 2030-10.
What conditions does trial NCT06789445 study?
This clinical trial studies the following conditions: Retinal Degeneration, Cone-Rod Dystrophy, Retinitis Pigmentosa (RP), Rod Cone Dystrophy, Primary Photoreceptor Disease.
What interventions are being tested in trial NCT06789445?
The interventions under investigation include: OpCT-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06789445?
This trial is sponsored by BlueRock Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06789445 being conducted?
This trial has 3 study locations across Florida, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06789445's enrollment target sits among peer trials
54 9th of 17 higher than 9 of 17 other Retinal Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinal Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
RECRUITING · Phase 1
-
Oral Metformin for Treatment of ABCA4 Retinopathy
RECRUITING · Phase 1
-
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
RECRUITING · Phase 1
-
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
COMPLETED · Phase 1
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Cell Collection to Study Eye Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI